Guillain Barre Syndrome Treatment Market 2022 Analysis May Set New Growth Story, Forecast to 2028
The global Guillain barre syndrome treatment market is anticipated to grow at a significant CAGR of 5.2% during the forecast period 2022-2028. As per the information provided by the United Nations, in 2020, there are an estimated 727 million persons aged 65 years or over across. Additionally, this number is projected to be more than double by 2050, reaching over 1.5 billion persons. So, the increasing elderly population, which leads to the pervasiveness of immunological illnesses is one of the primary factors driving the expansion of the guillain barre syndrome market.
To Request a Sample of our Report on Guillain
Barre Syndrome Treatment Market: https://www.omrglobal.com/request-sample/guillain-barre-syndrome-treatment-market
Further, the key
players operating in the global guillain barre syndrome treatment market had
been adopting strategies such as new launches and agreements to gain major
market share. For instance, in November 2021, Biotest AG announced the
authorization in France for the human intravenous immunoglobulin preparation
that is Intratect which is manufactured and marketed by Biotest in two
concentrations. The Intratect is an important component of Biotest's portfolio
with over 50 approvals globally. The broad spectrum of indications includes
substitution therapy for primary and secondary immunodeficiency diseases along
with immunomodulation for primary immune thrombocytopenia, Guillain-Barré
syndrome, and Kawasaki syndrome, among others. Further, in September 2019,
Annexon Biosciences Inc., announced that the FDA had granted fast track
designation to ANX005, a novel treatment for Guillain-Barré syndrome. ANX005 is
a clinical-stage investigational monoclonal antibody intended to treat patients
with autoimmune and neurodegenerative disorders and formulated for IV administration.
Market Coverage
·
The market number available for – 2021-2028
·
Base year- 2021
·
Forecast period- 2022-2028
Segment Covered-
·
By Type
·
By Distribution Channel
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape - including, Bayer AG, Grifols SA, CSL Ltd.,
Octapharma AG, Kedrion Biopharma Inc., and Takeda Pharmaceutical Co. Ltd.,
among others.
(Get 15% Discount on Buying this Report)
A
full Report of Guillain Barre Syndrome Treatment Market is Available @ https://www.omrglobal.com/industry-reports/guillain-barre-syndrome-treatment-market
Global Guillain Barre Syndrome Treatment Market Report Segment
By Type
·
Intravenous Immunoglobulin
·
Plasma Exchange
·
Others (Anticonvulsants and LMWH)
By Distribution Channel
·
Hospital Pharmacy
·
Retail Pharmacy
·
Others
Global Guillain Barre Syndrome Treatment Market Report Segment by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Company Profiles
·
Akari Therapeutics Inc.
·
Annexon Biosciences Inc.
·
Bayer AG
·
Biotest AG
·
China Biologic Product Holdings Inc.
·
CSL Ltd.
·
CuraVac Inc.
·
Grifols SA
·
Hansa Medical AB
·
Kedrion Biopharma Inc.
·
Nihon Pharmaceutical Co. Ltd.
·
Octapharma AG
·
Takeda Pharmaceutical Co. Ltd.
·
Vitality Biopharma Inc.
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment